These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22497849)

  • 1. Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial.
    Yakoot M; Salem A
    BMC Gastroenterol; 2012 Apr; 12():32. PubMed ID: 22497849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study].
    Pár A; Roth E; Miseta A; Hegedüs G; Pár G; Hunyady B; Vincze A
    Orv Hetil; 2009 Jan; 150(2):73-9. PubMed ID: 19103558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.
    Fried MW; Navarro VJ; Afdhal N; Belle SH; Wahed AS; Hawke RL; Doo E; Meyers CM; Reddy KR;
    JAMA; 2012 Jul; 308(3):274-82. PubMed ID: 22797645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
    Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
    Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a herbal mixture (Viron® tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective, randomized, open-label, proof-of-concept study.
    Shawkat H; Yakoot M; Shawkat T; Helmy S
    Drug Des Devel Ther; 2015; 9():799-804. PubMed ID: 25709404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    El-Zayadi AR; Attia M; Badran HM; El-Tawil A; Zalata K; Barakat E; Selim O; El-Nakeeb A; Saied A
    Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.
    Basso M; Giannini EG; Torre F; Blanchi S; Savarino V; Picciotto A
    Hepatology; 2009 May; 49(5):1442-8. PubMed ID: 19350657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT.
    Al-Ali J; Siddique I; Varghese R; Hasan F
    Ann Hepatol; 2012; 11(2):186-93. PubMed ID: 22345335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C.
    Reddy KR; Belle SH; Fried MW; Afdhal N; Navarro VJ; Hawke RL; Wahed AS; Doo E; Meyers CM;
    Clin Trials; 2012 Feb; 9(1):102-12. PubMed ID: 22058086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C.
    Gordon A; Hobbs DA; Bowden DS; Bailey MJ; Mitchell J; Francis AJ; Roberts SK
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):275-80. PubMed ID: 16460486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral silymarin for chronic hepatitis C - a retrospective analysis comparing three dose regimens.
    Huber R; Futter I; Lüdtke R
    Eur J Med Res; 2005 Feb; 10(2):68-70. PubMed ID: 15817425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
    Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
    Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
    Seeff LB; Curto TM; Szabo G; Everson GT; Bonkovsky HL; Dienstag JL; Shiffman ML; Lindsay KL; Lok AS; Di Bisceglie AM; Lee WM; Ghany MG;
    Hepatology; 2008 Feb; 47(2):605-12. PubMed ID: 18157835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
    Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
    Guptan RC; Thakur V; Kazim SN; Sarin SK
    J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
    Brillanti S; Foli M; Di Tomaso M; Gramantieri L; Masci C; Bolondi L
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):130-4. PubMed ID: 10363198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin.
    Polyak SJ; Morishima C; Shuhart MC; Wang CC; Liu Y; Lee DY
    Gastroenterology; 2007 May; 132(5):1925-36. PubMed ID: 17484885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.
    Köse Ş; Senger SS; Ersan G; Çavdar G
    Clin Exp Nephrol; 2013 Feb; 17(1):115-9. PubMed ID: 22814955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.